The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending marketing authorization for Wegovy (once-weekly semaglutide 2.4mg injection), from Danish diabetes care giant Novo Nordisk (NOV: N), chronic weight management in adults with obesity.
Wegovy is intended for chronic weight management in adults living with obesity (initial BMI≥30 kg/m2) or overweight (initial BMI≥27 kg/m2) with at least one weight-related comorbidity such as high blood pressure, heart disease or type 2 diabetes.
The positive CHMP opinion is based on results from the STEP Phase IIIa clinical trial program. Across the trials in people with obesity or overweight without type 2 diabetes, an average weight loss of 17-18% sustained over 68 weeks was reported for those treated with Wegovy. Wegovy demonstrated a safe and well-tolerated profile across the program, with the most common adverse events being gastrointestinal.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze